絞り込み

16555

広告

職員以外も加算 ケアマネなど、処遇改善 (毎日新聞)

厚生労働省は15日、来年10月の消費増税に合わせた介護職員の処遇改善策について、介護報酬の加算分を介護職員以外の職種の給与増に使うことを認める方針を示した。対象...

  1. 温暖化でビール高値に 大麦の収穫減で -...
  2. 温暖化でビール高値に - 徳島新聞
  3. 温暖化でビール高値に (デイリースポーツ...
  4. 温暖化でビール高値に 大麦の収穫減、今世...

ニュース一覧

Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors.

著者 Singh M , Jadhav HR
Drug Discov Today.2017 Oct 11 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (56view , 0users)

Full Text Sources

Miscellaneous

Epidermal growth factor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, show excellent clinical efficacy for patients with non-small cell lung cancer (NSCLC) with EGFR mutations, including Exon 19 deletion and single-point substitution, and L858R of exon 21. The reason for the reduction in effectiveness of these EGFR TKIs is the T790M gatekeeper mutation in the ATP-binding pocket of Exon 20, which increases the affinity of EGFR for ATP. Newer EGFR TKIs, such as afatinib, osimertinib, rociletinib, EGF816 and ASP8273, selectively target T790M mutants, sparing wild-type EGFR. EGFR TKIs have fewer adverse effects than chemotherapy and also improve progression-free survival. Combination therapy of EGFR TKIs with anti-EGFR antibodies is recommended for overcoming the problem of resistance to some extent. This review could help medicinal chemists to design novel EGFR TKIs against NSCLC.
PMID: 29031620 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード